Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Requests Addl. Data On Novartis' Menveo For Expanded Use In Infants,toddlers

RELATED NEWS
Trade NVS now with 

Novartis (NVS: Quote) said it has received a Complete Response letter from the US Food and Drug Administration or FDA on its application for the expanded use of Menveo in infants and toddlers from 2 months of age.

Novartis submitted the supplemental Biologics License Application or sBLA for Menveo to the FDA in April 2011. The Complete Response letter indicated that the FDA has completed the current review cycle and requests answers to additional questions prior to proceeding with further review of the sBLA. Novartis would work with the FDA to address these questions.

Meningococcal Oligosaccharide Diphtheria CRM Conjugate Vaccine, Menveo, is already approved for use in individuals 2 to 55 years of age in the U.S.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
At least 15 people, including women and children, were killed in an overnight Israeli attack on a UN school housing refugees in Gaza, reports say. The UN Relief and Works Agency (UNRWA) confirmed it, and put the blame on Israel. The children were sleeping next to their parents on the floor of a classroom in a UN designated shelter in Gaza, when Israeli artillery hit them, UNRWA said in a stateme After turning lower over the course of the previous session, stocks are likely to move back to the upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 59 points. Eurozone banks eased the credit standards for lending to businesses for the first time since the second quarter of 2007, the European Central Bank said in a report on Wednesday, helping to support economic recovery. "Credit standards for all loan categories eased in net terms in the second quarter...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.